Metformina Hexal (Metformin Hydrochloride)

Metformina Hexal, a biguanide antidiabetic, acts on glucose metabolism pathways to control hyperglycaemia.

• Type 2 diabetes mellitus: improves glycaemic control and reduces fasting plasma glucose.
• Gestational diabetes mellitus: helps maintain target glucose levels during pregnancy.
• Prediabetes (impaired glucose tolerance): may delay progression to overt diabetes when combined with lifestyle measures.

• Metformin lowers blood glucose primarily by inhibiting hepatic gluconeogenesis, thereby reducing hepatic glucose output. It also enhances peripheral insulin sensitivity by increasing glucose uptake in muscle and adipose tissue and modestly decreases intestinal absorption of glucose. These actions are mediated through activation of AMP‑activated protein kinase (AMPK) and related metabolic pathways, without directly stimulating insulin secretion.

Metformina Hexal may cause a range of adverse reactions, most of which are related to the gastrointestinal tract, while rare but serious events require prompt medical attention.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhoea: frequent loose stools, especially at treatment initiation.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: transient alteration in taste perception.
• Loss of appetite: reduced desire to eat.
• Flatulence: increased intestinal gas.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening metabolic disturbance.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Hypoglycaemia: when combined with other glucose‑lowering agents.
• Vitamin B12 deficiency: long‑term use may impair absorption.
• Acute pancreatitis: rare inflammatory condition of the pancreas.

Before initiating Metformina Hexal, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Renal function assessment: ensure adequate kidney clearance before starting and periodically thereafter.
• Hepatic status review: avoid use in patients with significant liver disease.
• Lactic acidosis risk: contraindicate in conditions predisposing to hypoxia or severe infection.
• Elderly dosing: consider lower starting dose and close monitoring.
• Alcohol consumption: advise patients to limit alcohol to reduce lactic acidosis risk.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metformina Hexal can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure, increasing lactic acidosis risk.
• Cimetidine: can raise plasma metformin concentrations, enhancing toxicity.
• Alcohol: synergistic effect on lactic acidosis development.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycaemia symptoms.
• Diuretics (loop or thiazide): can affect renal clearance of metformin.
• ACE inhibitors or ARBs: monitor renal function and electrolytes.
• NSAIDs: may impair renal function, increasing metformin exposure.
• Calcium channel blockers: occasional reports of altered glucose control.